Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Is Supernus Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of October 2, 2026, Supernus Pharmaceuticals, Inc. (SUPN) trades at $43.04 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Supernus Pharmaceuticals, Inc.
Market cap $2B · 52 weeks $41 – $57 (25 % below the high) · P/E no earnings · 2027 expected P/E 9.7× · Dividend none · Next earnings November 3, 2026 · expected EPS $0.61 · Price as of Oct 2 · accounts published Aug 3.
- Valuation: P/Sales 2.9× (no earnings).
- Business: ROIC −9 % (weak).
- Balance sheet: Net debt/EBITDA −2.1× (solid).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 2 of 4 pass
- ROIC −9.1 %, fails.
- R&D / Revenue 14.8 %, borderline.
- Gross margin 89.6 %, passes.
- Net debt / EBITDA −2.1×, passes.
Against its peers (reference peers) — Supernus Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -9.1 %; $2.5B. HUTCHMED (China) Limited (P/E 155×; EV/EBITDA —; ROIC -3.3 %; $2.5B), Bausch Health Companies Inc. (P/E —; EV/EBITDA 7.1×; ROIC 3.2 %; $2.2B), Indivior Pharmaceuticals Inc (P/E 12.6×; EV/EBITDA 15.3×; ROIC 70.8 %; $4.5B).
Profitability
| Return on Equity | -10.42% |
| Return on Invested Capital | -9.12% |
| Return on Assets | -7.69% |
| Gross Margin | 88.07% |
| Operating Margin | -13.46% |
| Net Margin | -13.23% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 2.08 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 5.47 |
Price Performance
| 1 month | -1.77% |
| 3 months | -15.23% |
| Year-to-date | -13.96% |
| 1 year | -11.49% |
| 3 years | +55.83% |
| 5 years | +59.43% |
Related companies: AMRX · BHC · CGON · GRAL · HCM · INDV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SUPN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks